Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte, Inc. (Nasdaq: VCYT) announced the publication of a manuscript outlining its next-generation Percepta® Genomic Sequencing Classifier (GSC) aimed at enhancing lung cancer diagnosis. The paper, available in BMC Medical Genomics, presents a genomic classifier that improves diagnostic accuracy for patients with inconclusive bronchoscopy results. This classifier utilizes advanced RNA sequencing and machine learning on samples from over 1,600 patients, enhancing predictive capabilities and potentially reducing the need for invasive procedures.
Veracyte, Inc. (Nasdaq: VCYT) presented research at the CHEST Annual Meeting 2020, showing that a genomic smoking index can be detected in nasal samples, supporting their noninvasive nasal swab test for lung cancer risk assessment. This test aims to differentiate between high and low-risk patients with lung nodules, potentially streamlining diagnosis and treatment. Early data is expected before 2020 ends, with a U.S. launch projected in the second half of 2021. The findings emphasize the importance of early lung cancer detection for improved survival rates.
Veracyte (Nasdaq: VCYT) is set to present at the CHEST Annual Meeting 2020, highlighting its innovative noninvasive nasal swab test designed to assess lung cancer risk in patients with lung nodules. The virtual meeting occurs from October 18-21, 2020. Bonnie Anderson, CEO, emphasized the transformative potential of this technology, which utilizes 'field of injury' to detect genomic signals. Lung cancer remains the leading cancer death cause in the U.S., with nearly 160,000 fatalities annually, underlining the urgency for accurate diagnostics.
Veracyte, Inc (Nasdaq: VCYT) will release its third quarter 2020 financial results after market close on November 2, 2020. The management will host a conference call at 4:30 p.m. ET the same day to discuss the results and provide a business update. A live webcast of the call will be accessible on the company's website, with a replay available for one year post-broadcast. Veracyte specializes in genomic diagnostics, offering tests for various cancers and diseases, aimed at improving patient care and diagnostic efficiency.